nivolumab,ipilimumab,cabozantinib
exelixis,bms
['ipi/', 'nivo', 'cosmic 313', 'triplet,(-triplete)']
cosmic 313 presented by the great . pfs benefit and os not ready yet. first triplet therapy presented compared against contemporary control (ipi/nivo). fewer nephrectomies. cr rate is low in both arms 3%. looking forward to os data when available. #esmo22 
A medical oncologist that specializes in and focuses his research on urologic cancers.